SCHEMBL4138474

SCHEMBL4138474

CCOC(=O)C(CC1CC1)C(C)=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP2D6 P10635 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GAA P10253 2/20 0.33
ALOX15 P16050 1/20 0.32
MGAM O43451 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
SOAT1 P35610 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NOS3 P29474 1/20 0.32
NOS2 P35228 1/20 0.32
MMP8 P22894 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139331 0.93 L3MBTL1 (0.36) ALDH1A1LMNAHSD17B10L3MBTL1CYP2D6
SCHEMBL8784684 0.91 METAP2 (0.40) ALDH1A1L3MBTL1CYP2D6NPSR1
SCHEMBL9219750 0.90 L3MBTL1 (0.41) ALDH1A1LMNAHSD17B10L3MBTL1CYP2D6
SCHEMBL25381770 0.86 L3MBTL1 (0.39) ALDH1A1LMNAHSD17B10L3MBTL1TDP1
SCHEMBL10708317 0.85 TRPM8 (0.38) ALDH1A1LMNAHSD17B10L3MBTL1CYP2D6
SCHEMBL10708312 0.85 TRPM8 (0.38) ALDH1A1LMNAHSD17B10L3MBTL1CYP2D6
SCHEMBL31678956 0.83 ANPEP (0.36) LMNAKMT2ATDP1
SCHEMBL1009487 0.82 L3MBTL1 (0.39) ALDH1A1LMNAHSD17B10L3MBTL1CYP2D6
SCHEMBL855134 0.82 CNR2 (0.33)
SCHEMBL16732371 0.82 METAP2 (0.40) ALDH1A1L3MBTL1CYP2D6NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018114541-A2 MICROBIOCIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-06-28 WO disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
US-20090137557-A1 Calcilytic Compounds SMITHKLINE BEECHAM CORPORATION 2009-05-28 US disclosed
CN-101360498-A Calcilytic compounds SMITHKLINE BEECHAM CORP (US) 2009-02-04 CN disclosed
EP-1951244-A2 CALCILYTIC COMPOUNDS SmithKline Beecham Corporation (US) 2008-08-06 EP disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed
WO-2007062370-A2 CALCILYTIC COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137557-A1 Calcilytic Compounds CALCR, SOST, CALCB ALDH1A1 4674/4885LMNA 1316/4885HSD17B10 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.